Brown Gibbons Lang Facilitates Sale of USDTL to Northlane Capital Partners

Strategic Acquisition in Forensic Toxicology

In a significant move within the healthcare sector, Brown Gibbons Lang & Company (BGL), a prominent investment bank specializing in financial advisory services, has managed the sale of the United States Drug Testing Laboratories Inc. (USDTL) to Northlane Capital Partners (NCP). Announced on January 13, 2025, this transaction aims to enhance forensic toxicology capabilities and broaden the spectrum of lab services provided by USDTL.

Overview of the Sale

The transaction marks a pivotal shift for USDTL, a well-established leader in forensic toxicology testing, renowned for its laboratory services that cater to a diverse clientele, including hospitals, health systems, and law enforcement agencies. With a workforce of over 160 employees and a customer base exceeding 1,000 both domestically and internationally, USDTL has built a reputation for delivering reliable and advanced specimen testing solutions.

BGL’s Healthcare and Life Sciences investment banking team served as the exclusive financial advisor to USDTL during this critical transition. While the specific financial terms of the sale have not been disclosed, experts predict that this partnership will leverage Northlane’s extensive experience in healthcare and lab services to enhance USDTL’s testing capabilities.

Benefits of the Partnership

The collaboration between NCP and USDTL is anticipated to be mutually beneficial. For NCP, acquiring USDTL opens up opportunities to further develop and implement efficient laboratory services. On the other hand, USDTL will gain access to NCP's expertise and resources, enabling the company to expand its advanced testing capabilities and strengthen its robust customer base.

Additionally, NCP’s background in healthcare private equity provides the necessary capital and strategic insight that USDTL needs to innovate and grow in a competitive market.

About USDTL

Headquartered in Des Plaines, Illinois, USDTL has long been at the forefront of forensic toxicology. The organization specializes in testing for alcohol and substance use, offering accurate results that serve a broad array of sectors including employment screening, court systems, and healthcare institutions. As a trusted partner for businesses seeking to uphold stringent testing standards, USDTL’s services play a crucial role in public health and safety.

BGL: A Leader in Investment Banking

Brown Gibbons Lang & Company (BGL) prides itself on its extensive experience in advising companies across various sectors, particularly in healthcare and life sciences. The firm has established strong relationships with key participants in the global healthcare landscape, thereby facilitating successful mergers and acquisitions, financial restructuring, and corporate valuations.

With offices in major cities including Boston, Chicago, and New York, BGL has positioned itself as a go-to advisor for both private corporations and private equity firms looking to navigate complex financial landscapes. Their commitment to understanding regulatory trends and market demands ensures that their clients receive insightful and strategic advice tailored to their needs.

Conclusion

The sale of USDTL to Northlane Capital Partners signifies a proactive step towards enhancing laboratory services and advancing forensic testing capabilities in the market. As both organizations embark on this partnership, industry observers will be keenly watching how this alliance transforms the landscape of forensic toxicology and healthcare standards in the United States.